ClinicalTrials.gg
Status unknownNCT05532579Updated Sep 8, 2022

Effectiveness of an Invasive Physical Therapy Protocol in Primary Care Patients With Low Back Pain. Randomized Controlled Clinical Trial

An interventional study of Invasive Physiotherapy Group and Sham Group in Low Back Pain, sponsored by Universitat Internacional de Catalunya. Status unknown at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-08.

Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Low back pain or lumbar pain is the most frequent cause of incapacity for work in Spain, occupying first place among the most common pathologies diagnosed in this country, followed by cervical pain. Non-specific low back pain is the main cause of public spending on health care and labor concepts, with a prevalence of 80%. Furthermore, this pathology represents more than half (52.92%) of the diagnoses of chronic pain that is neither oncologic nor neuropathic. This situation generates high economic, health care and labor costs, representing an equivalent cost of between 1.7% and 2.1% of the Gross Domestic Product.

Low back pain is described as pain located between the lower limit of the ribs and the lower limit of the buttocks, the intensity of which varies according to posture and physical activity, and which is usually accompanied by painful limitation of movement. Approximately 40% of patients with low back pain present irradiation in the lower extremity. The chronification of low back pain can result in central sensitization, causing hypersensitivity to non-painful and painful stimuli even long after the onset of the acute episode of low back pain.

The approach to low back pain offers options such as the administration of drugs, prescription of physical exercise, pain education and modification of patients' habits. Minimally invasive techniques in the management of low back pain are arousing greater interest due to their great advantages. In the field of physical therapy, novel techniques have been developed in recent years, such as ultrasound-guided percutaneous musculoskeletal electrolysis and ultrasound-guided percutaneous neuromodulation, in which different types of electric current are applied through solid needles. Different mechanisms of action have been associated with these invasive techniques, such as a potential effect on the activation of descending pain inhibitory system pathways, the reduction of evoked motor potentials and an increase in intracortical inhibition, suggesting benefits in patients with central sensitization. The invasive techniques of electrolysis and neuromodulation have been applied in other studies at the nervous level, especially in the sciatic nerve at the piriformis and ischiotibial level, in the popliteal fossa and in the foot. It has given good results in lumbar pain. However, there is no study carried out in patients with low back pain and the presence of hernias or protrusions, nor is there any control of the evolution in the medium and long term.

The application of percutaneous neuromodulation has the capacity to modulate neuronal activity in the primary motor cortex, promoting transient and long-term neuroplastic effects. The modulation of this region is related to a decrease in pain due to the relationship with pain processing areas, such as the thalamus, cingulate cortex and periaqueductal gray matter. Electrical stimulation of the peripheral nervous system percutaneously activates a complex neural network that in turn involves a series of neurotransmitters and receptors, such mechanisms being able to promote segmental analgesia and extra-segmental analgesia. Some studies suggest that percutaneous neuromodulation therapy may have a possible beneficial effect in patients with central sensitization, producing improved conditioned pain modulation, reduced motor evoked potential and enhanced intracortical inhibition.

To the authors' knowledge, there are no studies that prove the effectiveness of these invasive techniques in the improvement of neurophysiological parameters in patients with low back pain with irradiation in the lower extremity, presence of hernias and/or protrusions. Taking into account the good empirical results found in private clinics and the precedents of other studies carried out with short-term follow-up in other regions, this treatment approach of outpatient application in primary care centers could mean a discharge of patients who are referred to the hospital for medical care, imaging tests and surgical interventions.

Read the detailed description

Low back pain or lumbar pain is the most frequent cause of incapacity for work in Spain, occupying first place among the most common pathologies diagnosed in this country, followed by cervical pain. Non-specific low back pain is the main cause of public spending on health care and labor concepts, with a prevalence of 80%. Furthermore, this pathology represents more than half (52.92%) of the diagnoses of chronic pain that is neither oncologic nor neuropathic. This situation generates high economic, health care and labor costs, representing an equivalent cost of between 1.7% and 2.1% of the Gross Domestic Product.

Low back pain is described as pain located between the lower limit of the ribs and the lower limit of the buttocks, the intensity of which varies according to posture and physical activity, and which is usually accompanied by painful limitation of movement. Approximately 40% of patients with low back pain present irradiation in the lower extremity. The chronification of low back pain can result in central sensitization, causing hypersensitivity to non-painful and painful stimuli even long after the onset of the acute episode of low back pain.

The approach to low back pain offers options such as the administration of drugs, prescription of physical exercise, pain education and modification of patients' habits. Minimally invasive techniques in the management of low back pain are arousing greater interest due to their great advantages. In the field of physical therapy, novel techniques have been developed in recent years, such as ultrasound-guided percutaneous musculoskeletal electrolysis and ultrasound-guided percutaneous neuromodulation, in which different types of electric current are applied through solid needles. Different mechanisms of action have been associated with these invasive techniques, such as a potential effect on the activation of descending pain inhibitory system pathways, the reduction of evoked motor potentials and an increase in intracortical inhibition, suggesting benefits in patients with central sensitization. The invasive techniques of electrolysis and neuromodulation have been applied in other studies at the nervous level, especially in the sciatic nerve at the piriformis and ischiotibial level, in the popliteal fossa and in the foot. It has given good results in lumbar pain. However, there is no study carried out in patients with low back pain and the presence of hernias or protrusions, nor is there any control of the evolution in the medium and long term.

The application of percutaneous neuromodulation has the capacity to modulate neuronal activity in the primary motor cortex, promoting transient and long-term neuroplastic effects. The modulation of this region is related to a decrease in pain due to the relationship with pain processing areas, such as the thalamus, cingulate cortex and periaqueductal gray matter. Electrical stimulation of the peripheral nervous system percutaneously activates a complex neural network that in turn involves a series of neurotransmitters and receptors, such mechanisms being able to promote segmental analgesia and extra-segmental analgesia. Some studies suggest that percutaneous neuromodulation therapy may have a possible beneficial effect in patients with central sensitization, producing improved conditioned pain modulation, reduced motor evoked potential and enhanced intracortical inhibition.

To the authors' knowledge, there are no studies that prove the effectiveness of these invasive techniques in the improvement of neurophysiological parameters in patients with low back pain with irradiation in the lower extremity, presence of hernias and/or protrusions. Taking into account the good empirical results found in private clinics and the precedents of other studies carried out with short-term follow-up in other regions, this treatment approach of outpatient application in primary care centers could mean a discharge of patients who are referred to the hospital for medical care, imaging tests and surgical interventions.

02

Conditions studied

  • Low Back Pain

Browse trials for

03

In context

Low Back Pain

2,875 studies on the registry are indexed under Low Back Pain; 484 are open to participants now.

This study's planned enrollment of 38 is below the median of 60 across 2,315 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Universitat Internacional de Catalunya is the lead sponsor of 150 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age equal to or more than 18 years old.
  • Have a medical diagnosis of low back pain with or without radicular involvement and irradiation of symptoms in the lower extremity, by the specialist of the Neurophysiology Service of the Hospital de Terrassa "Consorci Sanitari de Terrassa" or of the Hospital Clínico Universitario de Zaragoza, with confirmation of neurophysiological study, in any of its stages.
  • Have access and be able (or have help) to use an online platform to conduct "meetings" with the health professional.
  • Read the informed consent and understand the objectives and development of the study.

Exclusion criteria

Exclusion Criteria:

  • Be pending compensation or litigation for health problems.
  • Receiving physiotherapeutic treatment in the region in the month prior to the study.
  • Present severe diseases that may be related to the clinical results: malignancy or history of cancer, tumors or fractures in the region to be treated, blood dyscrasia, severe trauma in the previous 3 months, surgery in the region in the previous 12 months.
  • Present contraindications to the therapeutic approach such as: Belonephobia (fear of needles), coagulation alteration, history of adverse reactions, patients reluctant to this type of treatment.
  • Subjects who have previously received percutaneous neuromodulation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Invasive Physiotherapy

    Other: Invasive Physiotherapy Group

  • Placebo comparator
    Sham Group

    Other: Sham Group

Interventions

  • OtherInvasive Physiotherapy Group

    The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.

  • OtherSham Group

    Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.

06

What researchers measure

Primary outcomes

  1. Change in Present Pain Intensity (NPRS 0-10)

    The intensity of hand pain will be recorded, using an 11-point numerical scale (NPRS) (0=no pain, 10=maximum pain). They will be asked for current pain. Because there is no value that determines the minimum clinically relevant difference in hand pain, a 2-point change, or 30% change, will be considered clinically relevant

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

Secondary outcomes

  1. Change in Neurophysiological study (m/s)

    The procedures will be performed by a neurophysiologist with more than 10 years of clinical and research experience using an electroneurogram (needles, electrodes and nerve conduction information processors). The electrophysiological diagnostic criteria for low back pain and lumbar nerve root involvement of the American Association of Neuromuscular and Electrodiagnostic Medicine and the normal ranges of motor and sensory nerve conduction as described in the literature will be used. The following will be taken as study variables: existence of denervation, distal motor latency of the sciatic nerve, distal sensory latency of the sciatic nerve, conduction velocity, action potential amplitude.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  2. Change in straight leg elevation test (range of motion)

    The straight leg elevation test will be used to determine the mechanosensitivity of the sciatic nerve. In this test, a structural differentiation of the symptoms will be made at a distance from the area of symptom onset. Performing an internal rotation of the hip if the symptoms are distal (below the knee) or with a dorsiflexion of the ankles if the symptoms are proximal. This test has obtained consistent values in patients with low back pain, with good inter-examiner reliability in its application.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  3. Roland Morris disability Questionnaire

    Questionnaire to determine the degree of physical disability derived from low back pain. A self-administered questionnaire consisting of 24 sentences in which the patient has to indicate whether they relate to his or her current situation or not. Score from 0 to 24.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  4. Change in Global rating of change scale

    Scale of global change perceived by the patient, designed to detect improvement or deterioration of the patient over time. An 11-point numerical scale (-7=evolving to much worse; +7=fully recovered). Considering +4 and +5 moderate positive changes and +6 and +7 notable changes.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  5. Change in lower extremity strength (Newtons)

    The strength of the affected lower extremity will be measured with a hand-held dynamometer (MicroFET 2). The functional movements of hip flexion and extension, knee flexion and extension and ankle flexion and extension will be measured. Three measurements per movement will be taken and the average of them will be obtained.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  6. Change in Sensitivity (discrimination of two points)

    The discrimination of two points on the back of the thigh, on the front and back of the leg and the entire region of the foot and ankle will be assessed with a digital caliper. Pressure will be applied with one or two points until causing some discomfort to the patient, having to discriminate whether the patient is stimulated with 1 or 2 points, the minimum distance that he/she manages to discriminate will be recorded. With the patient lying down with eyes closed, the patient will be asked to say "one" when he/she feels that he/she is touched with one point and "two" when he/she feels that he/she is touched with two points.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  7. Change in Sensitivity (Semmes-Weinstein Monofilament Test)

    Stimulation by means of pressure filaments, seeking to detect the sensitive threshold by means of 1-second pressures, the necessary pressure will be applied to cause a slight deformation of the filament. The numbers of the filaments (1.65-6.65) of Semmes-Weinstein Monofilament, correspond to a logarithmic function of the equivalent forces (0.0045-447 g). The lightest filament detected will be recorded. With the patient lying down, eyes closed, the subject is asked to verbally signal the moment he/she feels the stimulus in the region to be explored. The filament will be applied vertically over the assessment point, slowly, until the filament bends.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

  8. Change in Inhibitory modulation conditioned by pain (Kpa)

    It will be performed with the aim of exploring the descending inhibitory pathway. In a first term, the test of pain thresholds by pressure in the affected area is performed. A remote area, usually the arm or hand, is subjected to a painful stimulus (ice cube) or ischemia cuff (maximum 10 min at 200 mmHg or up to VAS 6). At that time, the pressure pain threshold test is repeated on the affected area. An increase in the value of the pressure threshold test will denote a correct functioning of the inhibitory modulation.

    Time frame: Baseline; 1 month follow-up; 6 month follow-up

07

Study locations

1 site
  • Universitat Internacional de Catalunya
    Sant Cugat del Vallès, Barcelona 08195, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2023; primary completion for Apr 2024, 12 months later.

Of 1,187 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 12 months is close to that.

Counting every sponsor, half of 1,246 studies reached it within 11 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 8, 2022
StartEst.
Apr 1, 2023
Primary completionEst.
Apr 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Sep 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05532579
Responsible party
Jacobo Rodríguez Sanz (Principal Investigator, Universitat Internacional de Catalunya) — Principal investigator
First posted
Sep 8, 2022
Start date
Apr 1, 2023 (estimated)
Primary completion
Apr 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Sep 8, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion